/L with 81% lymphocytes, 16% neutrophils, 3% monocytes; Hb level of 147 g/L; and a platelet count of 167 × 10 9 /L. The absolute lymphocyte count was 19.07 × 10 9 /L. Peripheral blood flow cytometry revealed 48.9% of analyzed cells co-expressing CD5, CD19, and CD23 but lacking surface immunoglobulin light chains, FMC7, CD10, CD103, and CD38. Bone marrow aspirate and biopsy showed hypercellular bone marrow with diffuse interstitial and focal paratrabecular lymphocytic infiltrate. The lymphocytes were mature, small, and positive for CD19, CD79a, PAX-5, CD5, CD23, and CD20 but negative for cyclin D1 and CD10. Conventional cytogenetic tests and FISH revealed a normal karyotype with no additional karyotypic abnormalities. IGHV gene mutation was positive by multiplex PCR [7] . However, the TP53 mutation and deletion were not detected. (Fig. 1A) . FISH confirmed the presence of p210 BCR-ABL transcript in all analyzed cells from the same cytogenetic sample (Fig. 1B) . Interestingly, mutated IGHV was still positive by multiplex PCR analysis. Therefore, the patient was diagnosed as having chronic phase CML transformed from CLL (Fig. 1) .
He was started on the first-generation tyrosine kinase inhibitor (TKI) imatinib at a dose of 400 mg daily in June 2017. Consequently, his complete blood count normalized, and his spleen shrank. He achieved a complete hematologic response within three months of imatinib treatment and demonstrated a complete molecular response with a BCR-ABL/ABL ratio of 0.01%. Currently, the patient is healthy and still on oral imatinib, while the mutated IGHV gene is still positive by multiplex PCR analysis as of March 2019.
In a small cohort of CLL patients, Richter's transformation (RT) to non-Hodgkin's lymphoma, including highly malignant diffuse large B-cell lymphoma, was frequently documented and had a poor prognosis [6] . Risk factors for CLL progression to RT include TP53 mutation or deletion, 14q, 17p deletion abnormalities, and unmutated IGHV status [8] . In the present patient, cytogenetic tests revealed a normal karyotype, and molecular studies confirmed the absence of the TP53 mutation and unmutated IGHV. He was characterized by the presence of p210 BCR/ABL transcript and t(9;22)(q34;q11.2). Most importantly, he had a favorable response to imatinib treatment and achieved complete molecular remission, unlike previous cases [3] [4] [5] .
IGHV mutations have been observed in CML patients who progressed to the blast crisis phase [9, 10] . Our patient presented with the absence of BCR/ABL p210 transcript and t(9;22)(q34; q11.2) after treatment with TKIs. However, mutated rearrangement of the IGHV gene was still observed. This result suggests that the two disorders developed from two different leukemia stem cells.
IGHV mutations in our patient were detected by a third-party authoritative testing agency. Because of the long time span since the detection of the IGHV mutations, the mutation figures of CLL and CML could not be provided, which is a limitation of our study.
In conclusion, we describe a case of the transformation of IGHV mutation in CLL into CML with a favorable response to imatinib therapy. The origin of the two disorders in the same or in two distinct cell clones can be demonstrated by means of molecular analysis of IGHV when IGHV-mutated CLL transformed into another malignancy with distinct molecular aberrations.
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